4174.TWOOBI

浩鼎 · Biotech and medical · Taipei Exchange · Taiwan

NT$78.40close Nov 17, 2026

Four figures

From the exchange's own figures. Each line says what it is based on.

Revenue growth
Revenue −31% this year to October 2026, against the same months last year.
Return on equity
It earns −97% a year on its shareholders' equity (9M 2026, annualised).
Equity and assets
Equity is 74% of its assets; the rest is owed to others.
Price and earnings
No P/E: the exchange publishes none when the last four quarters show a loss.

Size and price

As of Nov 17, 2026.

$314M

market cap · NT$10.3B

n/a

P/E · market median 16.1

0.0%

dividend yield

Sep 24, 2026+142%

Revenue, month by month

Taiwanese companies report revenue every month, by the 10th of the next.

October 2026
NT$2M

revenue in October 2026

-59%

on the same month last year

-31%

this year so far, on last year

The latest report

9M 2026, year to date, consolidated.

Revenue
NT$27M
Operating income-3,485% of revenue
−NT$954M
Net incometo shareholders
−NT$885M
Earnings per share
−NT$6.73
Total assets
NT$2.5B
Equity
NT$1.9B
Book value per share
NT$9.23

Also in biotech and medical

The largest listed peers in Taiwan, by market cap.

Source: Taiwan Stock Exchange and Taipei Exchange OpenAPI, published on data.gov.tw under the Open Government Data License, version 1.0. Ryufin computed the ratios, market cap and growth rates from that data. US dollar figures use the BIS TWD/USD rate. Prices are end of day. Price history on Ryufin starts on Sep 24, 2026 and grows by one close each trading day.